… A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology Key Updates Dr. Peter A. Beal joins … of RNA-based therapeutics, particularly in the area of RNAediting. As an expert in the field of ADAR and A-to-I …
… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … November 20 at 1:20-2:00 p.m. GMT Presentation at the 1 st RNAEditing Summit During the 1 st RNAEditing Summit to be held …
LEIDEN, the Netherlands, May 23, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the appointment of Dr.
Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints – Company plans to discuss findings with regulators and pr